Company Overview

Roche Holding AG is a global healthcare company focused on pharmaceuticals and diagnostics, operating at the intersection of science, data, and medicine. The company develops and commercializes innovative prescription medicines and in vitro diagnostic solutions, serving healthcare systems, hospitals, laboratories, and patients worldwide. Roche is widely recognized for its leadership in oncology, immunology, infectious diseases, and personalized healthcare, with diagnostics and pharmaceuticals designed to work together to improve clinical outcomes.

Founded in 1896 in Basel, Switzerland, Roche has evolved from a manufacturer of industrial chemicals and vitamins into one of the world’s largest biotechnology-driven healthcare groups. Its long-term strategy has emphasized internal research and development, complemented by selective acquisitions that strengthened its biotechnology and diagnostics capabilities. Roche’s unique positioning lies in its integrated Pharmaceuticals and Diagnostics businesses, enabling a personalized medicine approach that aligns targeted therapies with companion diagnostics.

Business Operations

Roche operates through two primary business segments: Pharmaceuticals and Diagnostics. The Pharmaceuticals segment generates the majority of revenue and focuses on prescription medicines, with major therapeutic areas including oncology, neuroscience, immunology, ophthalmology, and rare diseases. Key revenue drivers include biologic therapies and specialty medicines developed through Roche’s extensive in-house research organization and its majority-owned biotechnology subsidiary, Genentech.

The Diagnostics segment provides in vitro diagnostic solutions, including molecular diagnostics, clinical chemistry, immunodiagnostics, pathology, and near-patient testing. Roche generates revenue globally through direct sales and regional affiliates, supported by manufacturing and R&D facilities across Europe, North America, and Asia. The company controls significant proprietary technologies in biologics, molecular diagnostics, and data-driven healthcare platforms, and maintains long-standing collaborations with academic institutions, biotechnology firms, and healthcare providers.

Strategic Position & Investments

Roche’s strategy centers on innovation-driven growth, with sustained investment in research and development and a focus on areas of high unmet medical need. The company consistently ranks among the highest global spenders on pharmaceutical R&D, prioritizing oncology, neuroscience, immunology, and diagnostics that enable personalized healthcare. Strategic investments emphasize biologics, gene and cell therapies, and data-enabled diagnostics.

Major acquisitions have played a defining role in Roche’s portfolio, most notably Genentech, which underpins Roche’s biotechnology leadership, and Foundation Medicine, which expanded its capabilities in genomic profiling and precision oncology. Roche also maintains a portfolio of majority-owned and fully integrated subsidiaries in diagnostics and biotechnology, while selectively partnering with emerging biotech companies to access novel technologies and therapeutic platforms.

Geographic Footprint

Roche is headquartered in Basel, Switzerland, and operates in more than 100 countries worldwide. The company has a strong presence in Europe, North America, and Asia-Pacific, with the United States representing its single largest market for pharmaceutical sales. Manufacturing, research, and commercial operations are distributed globally, allowing Roche to support regional healthcare systems and regulatory environments.

Internationally, Roche exerts significant influence through its extensive R&D network, global supply chain, and regional commercial organizations. The company’s diagnostics business, in particular, maintains a broad footprint across hospitals and laboratories worldwide, reinforcing Roche’s position as a key supplier to healthcare infrastructure in both developed and emerging markets.

Leadership & Governance

Roche operates under a governance structure that separates strategic oversight from executive management, reflecting its long-term ownership orientation and emphasis on scientific excellence. The company’s leadership philosophy emphasizes sustainable value creation, patient-focused innovation, and rigorous scientific standards, supported by a strong corporate culture rooted in research integrity.

Key executives include:

• Thomas Schinecker – Chief Executive Officer
• Alan Hippe – Chief Financial Officer
• Teresa Graham – Chief Executive Officer, Diagnostics
• Levi Garraway – Chief Medical Officer and Head of Global Product Development
• Severin Schwan – Chairman of the Board

Roche’s executive leadership oversees global operations while maintaining close alignment with its scientific organizations and long-term strategic priorities.